Renato Alves

Renato Alves

Auto-generated profile, based on publicly available information

Renato Alves

European Molecular Biology Laboratory, Heidelberg, Baden-Württemberg

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in eLife
Verified
Journal Article
Open access
TSThomas Sb Schmidt
Thomas Sb Schmidt
MHMatthew R Hayward
Matthew R Hayward
LCLuis P Coelho
Luis P Coelho
SLSimone S Li
Simone S Li
PCPaul I Costea
Paul I Costea
PBPeer Bork
Peer Bork
The gastrointestinal tract is abundantly colonized by microbes, yet the translocation of oral species to the intestine is considered a rare aberrant event, and a hallmark of disease. By studying salivary and fecal microbial strain populations of 310 species in 470 individuals from five countries, we found that transmission to, and subsequent colonization of, the large intestine by oral microbes is common and extensive among healthy individuals. We found evidence for a vast majority of oral species to be transferable, with increased levels of transmission in colorectal cancer and rheumatoid arthritis patients and, more generally, for species described as opportunistic pathogens. This establishes the oral cavity as an endogenous reservoir for gut microbial strains, and oral-fecal transmission as an important process that shapes the gastrointestinal microbiome in health and disease.

4 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAlessio Milanese
Alessio Milanese
DMDaniel R Mende
Daniel R Mende
LPLucas Paoli
Lucas Paoli
GSGuillem Salazar
Guillem Salazar
HRHans-Joachim Ruscheweyh
Hans-Joachim Ruscheweyh
SSShinichi Sunagawa
Shinichi Sunagawa
Metagenomic sequencing has greatly improved our ability to profile the composition of environmental and host-associated microbial communities. However, the dependency of most methods on reference genomes, which are currently unavailable for a substantial fraction of microbial species, introduces estimation biases. We present an updated and functionally extended tool based on universal (i.e., reference-independent), phylogenetic marker gene (MG)-based operational taxonomic units (mOTUs) enabling the profiling of >7700 microbial species. As more than 30% of them could not previously be quantified at this taxonomic resolution, relative abundance estimates based on mOTUs are more accurate compared to other methods. As a new feature, we show that mOTUs, which are based on essential housekeeping genes, are demonstrably well-suited for quantification of basal transcriptional activity of community members. Furthermore, single nucleotide variation profiles estimated using mOTUs reflect those from whole genomes, which allows for comparing microbial strain populations (e.g., across different human body sites).

8 March 2022 in Gut
Verified
Journal Article
Open access
PDF file
EKEce Kartal
Ece Kartal
TSThomas S B Schmidt
Thomas S B Schmidt
EMEsther Molina-Montes
Esther Molina-Montes
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
JWJakob Wirbel
Jakob Wirbel
PBPeer Bork
Peer Bork
Background Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. Objective To explore the faecal and salivary microbiota as potential diagnostic biomarkers. Methods We applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case–control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case–control study (n=76), in the validation phase. Results Faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0.84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0.94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19–9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. Conclusion Taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible.

17 February 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SFSebastien Fromentin
Sebastien Fromentin
SFSofia Kirke Forslund
Sofia Kirke Forslund
KCKanta Chechi
Kanta Chechi
JAJudith Aron-Wisnewsky
Judith Aron-Wisnewsky
RCRima Chakaroun
Rima Chakaroun
OPOluf Pedersen
Oluf Pedersen
Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.

15 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
LCLuis Pedro Coelho
Luis Pedro Coelho
RARenato Alves
Renato Alves
ARAlvaro Rodriguez del RIo
Alvaro Rodriguez del RIo
PMPernille Neve Myers
Pernille Neve Myers
CCCarlos P. Cantalapiedra
Carlos P. Cantalapiedra
PBPeer Bork
Peer Bork

8 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SFSofia Kirke Forslund
Sofia Kirke Forslund
RCRima Chakaroun
Rima Chakaroun
MZMaria Zimmermann-Kogadeeva
Maria Zimmermann-Kogadeeva
LMLajos Marko
Lajos Marko
JAJudith Aron-Wisnewsky
Judith Aron-Wisnewsky
PBPeer Bork
Peer Bork